INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Open-market purchaseVerified data

ADAR1 Capital Management, LLC bought INM

10% Owner · InMed Pharmaceuticals Inc. · Common Shares

Side
BUY
Value
$300K
Shares
200.0K
Price
$1.5
Executed
May 19, 2026
Disclosed
May 21, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
May 19 executedMay 21, 2026 disclosed

INM · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
43/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+15 / 25

    $300K reported value · 33.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · INM

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    22
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$5.28
    4 sh
    		Oct 23, 2026Oct 27, 2026
    traded Oct 23, 2026
    		+4dSEC FORM 4

    Evidence

    22
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$1,434
    1,086 sh
    		Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    		+1dSEC FORM 4

    Evidence

    22
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$1.32
    1 sh
    		Oct 16, 2026Oct 20, 2026
    traded Oct 16, 2026
    		+4dSEC FORM 4

    Evidence

    22
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$1,301
    984 sh
    		Oct 15, 2026Oct 15, 2026
    traded Oct 15, 2026
    		+0dSEC FORM 4

    Evidence

    22
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$750
    564 sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    22
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$11K
    8,021 sh
    		Oct 14, 2026Oct 15, 2026
    traded Oct 14, 2026
    		+1dSEC FORM 4

    Evidence

    22
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$7,436
    5,601 sh
    		Oct 6, 2026Oct 8, 2026
    traded Oct 6, 2026
    		+2dSEC FORM 4

    Evidence

    22
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$4,051
    3,046 sh
    		Oct 7, 2026Oct 8, 2026
    traded Oct 7, 2026
    		+1dSEC FORM 4

    Evidence

    22
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$2,997
    2,256 sh
    		Oct 8, 2026Oct 8, 2026
    traded Oct 8, 2026
    		+0dSEC FORM 4

    Evidence

    25
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$11K
    8,340 sh
    		Sep 16, 2026Sep 16, 2026
    traded Sep 16, 2026
    		+0dSEC FORM 4

    Evidence

    25
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$37K
    28.5K sh
    		Sep 14, 2026Sep 16, 2026
    traded Sep 14, 2026
    		+2dSEC FORM 4

    Evidence

    32
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$70K
    54.3K sh
    		Sep 15, 2026Sep 16, 2026
    traded Sep 15, 2026
    		+1dSEC FORM 4

    Evidence

    40
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$110K
    68.6K sh
    		May 19, 2026May 21, 2026
    traded May 19, 2026
    		+2dSEC FORM 4

    Evidence

    47
    AM
    ADAR1 Capital Management, LLC10% Owner
    INMInMed Pharmaceuticals Inc.
    Open-market purchase
    		BUY$312K
    200.0K sh
    		May 19, 2026May 21, 2026
    traded May 19, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001940272-26-000008
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 19, 2026
    Published
    May 21, 2026
    Ingested by INSIDER
    Nov 5, 03:57 UTC
    Last re-read
    Nov 5, 03:57 UTC

    Extracted facts

    Filer
    ADAR1 Capital Management, LLC
    Role
    10% Owner
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    InMed Pharmaceuticals Inc.
    Ticker
    INM
    Shares
    200.0K
    Price per share
    $1.5
    Value
    $299,800
    Execution date (reported)
    May 19, 2026
    Owned after transaction
    800.0K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 200.0K
    • Price: $1.499

    = $299,800

    What this establishes

    ADAR1 Capital Management, LLC filed this Form 4 reporting a open-market purchase of INM on May 19, 2026. It became public on May 21, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    10% Owner
    ADAR1 Capital Management, LLCcik:0001940272
    Issuer
    InMed Pharmaceuticals Inc.cik:0001728328

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.